Detail

back to news

Valneva Announces Successful Outcome of its AGM

24.06.2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held as a closed session at its registered office on June 23, 2021.

Among the adopted resolutions were approval of the 2020 financial statements and delegations for the management board to increase Valneva’s share capital and/or to issue financial instruments.

Valneva also confirmed at its AGM that it expects to announce topline data for the Phase 3 trials of its single-shot chikungunya vaccine candidate this summer and of its inactivated COVID-19 vaccine candidate by September 2021.

The AGM’s voting results will be made available in the “Investors & Media” section of Valneva’s corporate website in the coming days.

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, as well as our established vaccine development capabilities, to develop prophylactic vaccines to address these diseases. We have leveraged our expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Valneva Investor and Media Contacts

Laetitia Bachelot-Fontaine
Director Investor Relations & Corporate Communications
M +33 (0)6 4516 7099
investors@valneva.com